Molecular structure of JNJ-26481585, CAS Number: 875320-29-9
JNJ-26481585 (CAS 875320-29-9)
Alternate Names:
Quisinostat
Application:
JNJ-26481585 is an HDAC1, HDAC2, HDAC4, HDAC10, and HDAC11 inhibitor
CAS Number:
875320-29-9
Molecular Weight:
394.5
Molecular Formula:
C21H26N6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
JNJ-26481585 (Quisinostat) is an HDAC inhibitor. It has a second generation histone deacetylase inhibitor with antineoplastic activities. It inhibits well for HDAC1 (IC50 = 0.11 nM), HDAC2 (IC50 = 0.33 nM), HDAC4 (IC50 = 0.64 nM), HDAC10 (IC50 = 0.46 nM), HDAC11 (IC50 = 0.37 nM).
JNJ-26481585 (CAS 875320-29-9) References
- The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. | Deleu, S., et al. 2009. Leukemia. 23: 1894-903. PMID: 19494837
- Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. | Deleu, S., et al. 2009. Cancer Res. 69: 5307-11. PMID: 19531653
- Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. | Tong, WG., et al. 2010. Leuk Res. 34: 221-8. PMID: 19682743
- Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. | Schreml, J., et al. 2013. Eur J Hum Genet. 21: 643-52. PMID: 23073311
- The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. | Maes, K., et al. 2014. Oncotarget. 5: 3115-29. PMID: 24833108
- Effect of histone deacetylase inhibitor JNJ-26481585 in pain. | Capasso, KE., et al. 2015. J Mol Neurosci. 55: 570-8. PMID: 25085711
- JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis. | Heinicke, U., et al. 2015. Oncotarget. 6: 37836-51. PMID: 26473375
- Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma. | Heinicke, U., et al. 2016. Oncogene. 35: 3729-41. PMID: 26616861
- Epigenetic Suppression of GADs Expression is Involved in Temporal Lobe Epilepsy and Pilocarpine-Induced Mice Epilepsy. | Wang, JG., et al. 2016. Neurochem Res. 41: 1751-60. PMID: 27220336
- Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. | Enßle, JC., et al. 2018. Cancer Lett. 428: 160-172. PMID: 29709701
- The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction. | He, B., et al. 2018. Int J Biol Sci. 14: 1845-1858. PMID: 30443188
- Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells. | Kommalapati, VK., et al. 2020. Mol Cell Biochem. 468: 21-34. PMID: 32146648
- CaMKII exacerbates heart failure progression by activating class I HDACs. | Zhang, M., et al. 2020. J Mol Cell Cardiol. 149: 73-81. PMID: 32971072
- Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. | Vitanza, NA., et al. 2021. Neuro Oncol. 23: 376-386. PMID: 33130903
- Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis. | Wang, X., et al. 2021. Toxicol Appl Pharmacol. 410: 115363. PMID: 33290780
Inhibitor of:
ASXL3, BAF57, BAGE4, BRMS1L, CHRAC17, Dmap1, Enzyme, FGF-2, FGF-8F, Fibroblast Growth Factor (FGF), FRYL, GAGE12G, Gal11, GATAD (GATA zinc finger domain containing), GATAD2A, H2-A, H2BFWT, Hat2, HDA2, HDAC1, HDAC10, HDAC11, HDAC2, HDAC4, HESL, Histone B, Histone cluster 1 H1E, Histone cluster 1 H4J, Histone cluster 2 H2AA3, Histone cluster 2 H2AC, Histone Z, LOC665622, MAGE-B18, MAGE-B3, MAGE-F1, Mi2-α, MOF, MORF4L2, Msx-3, NAP1L5, NHLRC3, Npcd, NWD1, OTTMUSG00000016789, OTTMUSG00000016790, OTTMUSG00000016887, OTTMUSG00000018888, p130 Cas, PHF21A, PI31, RBBP1, Sin3, Sin4p, Sum1, TAF II p70, TSSC4, YEATS2, Zfp868, ZMYM6NB, ZMYND12, and ZNF224.Activator of:
BRD3, CRLF3, Histone cluster 1 H2AA2, Histone cluster 1 H3H, Histone cluster 2 H3B, Histone H2A.V, Neuralized-2, PSMD2, SA-2, SPT16, and Trimethyl Histone H3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JNJ-26481585, 5 mg | sc-364515 | 5 mg | $321.00 | |||
JNJ-26481585, 50 mg | sc-364515A | 50 mg | $1224.00 |